NCT06498648

Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma

RecruitingPHASE1, PHASE2INTERVENTIONAL

Trial Details

Start: 2026-03-18Est. Completion: 2027-01-31

Enrollment target: 74 participants

Locations

UT MD Anderson Cancer Center, Houston, Texas, United States

Other microbiome trials you might be interested in

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated SarcomasPhase 3Recruiting

Metastatic Dedifferentiated LiposarcomaMetastatic Undifferentiated Pleomorphic SarcomaStage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8Unresectable Dedifferentiated LiposarcomaUnresectable Undifferentiated Pleomorphic Sarcoma

This phase III trial compares the effect of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) to chemotherap…

Phoenix, United StatesEst. completion Apr 18, 2032

View Trial →

A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated LiposarcomaPhase 2Recruiting

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.